FAQs

We employ around 51,700 people:

• 46% in Europe;
• 28% in the Americas
• 26.5% in Asia-Pacific

The total number of shares in issue at 31 March 2013 was 1,250 million.

AstraZeneca is traded on the London, New York and Stockholm Stock Exchanges. The symbol is AZN in all three markets.

AstraZeneca adheres to the International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) with appropriate conversion to US GAAP being shown in our financial statements.

Moody's :
Long term: A2, Short term: P-1, Outlook: Stable
Standard & Poor's :
Long term AA-, Short term A-1+, Outlook: Negative
Fitch :
Long term AA-, Short term F1+, Outlook: Stable

046353108

AstraZeneca reports in US dollars.

AstraZeneca will announce second quarter and half year results on Thursday 1 August 2013.

The date for the 2013 Annual General Meeting will be Thursday 25 April 2013.

AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca PLC of UK.

This information can be found in the financial results section.

For dividend information, please see this page:

• Latest Dividend

Yes it is possible to have your dividends paid directly into your bank or building society.

If you are a UK shareholder please complete the request for payment of dividend form and forward it to Equiniti (formerly Lloyds TSB Registrars).

If you are a US shareholder please go to the Investor Services section of the JP Morgan ADR website.

If you are a Swedish shareholder please contact your personal broker or if you hold a VPC account contact the VPC on +46 (0) 8 402 9000.

At present AstraZeneca does not have a dividend re-investment plan.

No, it is not possible to have your dividends paid gross.

Please visit our dividend section.

This will depend on where your shares are held:

If you are a UK shareholder either complete one of the online forms or alternatively call Equiniti (formerly Lloyds TSB Registrars) on 0800 389 1580.

If you are a Swedish shareholder please contact your broker or if you hold a VPC account call the VPC on 08 402 9000.

If you are a US shareholder please go to the JPMorgan Chase Bank website or alternatively call them on 888 697 8018.

As above.

A legal representative, Peter Haglund, has been appointed to act on behalf of minority shareholders. He can be contacted at Advokatfirman Sodermark, Box 14055, SE 104 40 Stockholm, Sweden, telephone +46 8 670 57 50 and fax +46 8 663 67 20.

24.50 GBP

Shares in Zeneca Group PLC acquired on demerger from ICI will be treated as having a base cost for capital gains tax purposes ascertained by reference to the values of Zeneca and ICI shares on 1 June 1993 calculated in accordance with the provisions of Section 272 of the Taxation of Chargeable gains Act 1992. The base cost of any holding of ICI Shares on that date will be adjusted on the same basis.

The relevant prices on The London Stock Exchange on 1 June 1993 were:
Zeneca - 625.75p and ICI - 631.75p

The base cost of the pre-merger ICI Shares will therefore be split between the post-demerger Zeneca and ICI Shares in the proportion:
Zeneca -- 0.49761 and ICI -- 0.50239

Astra AB and Zeneca PLC shares were merged on 6th April 1999.
1 Astra share : 0.5045 AstraZeneca share
1 Zeneca share : 1 AstraZeneca share

AstraZeneca demerged its agrochemical business on 13 November 2000.